|Bid||5.33 x 1400|
|Ask||5.40 x 3000|
|Day's Range||4.41 - 6.35|
|52 Week Range||1.83 - 32.93|
|Beta (5Y Monthly)||1.81|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 07, 2022 - Nov 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
Subscribe to Yahoo Finance Plus to view Fair Value for NVTA
Shares of Invitae (NYSE: NVTA) recently shot up like a rocket in response to a second-quarter earnings call that was a lot more positive than expected. Bringing comprehensive genetic information into mainstream medicine could make Invitae a top performer in the years ahead. Let's look a little closer at the company's performance this year to see if it's a smart stock to buy now and hold for the long run.
Invitae Corporation (NYSE: NVTA), which specializes in medical genetic testing, saw its shares climb as high as 23% this week, according to data from S&P Global Intelligence. The stock closed at $2.30 last Friday, then opened on Monday at $2.37. The stock has been volatile with a 52-week low of $1.83 and a high of $32.93.
Shares of San Francisco-based genetic testing and data company Invitae Corporation (NVTA) exploded higher after reporting earnings Tuesday night. After 6.5 trading hours on Wednesday, Invitae stock had nearly tripled in value before traders began cashing in some gains. In fact, on Thursday the stock has returned over half of yesterday’s gains, trading 47% lower. While investors were initially thrilled by the news, Morgan Stanley analyst Tejas Savant observed there were actually "no surprises" in